Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 14/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 12/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 8/20 | 0.40 |
| ▸ | IDH2 | P48735 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3262310 | 0.91 | ABCG2 (0.43) | MEN1NPC1GBA1KMT2AABCG2 | |
| SCHEMBL3268020 | 0.86 | MAPT (0.36) | NPC1KMT2ARAB9AMAPT | |
| SCHEMBL3236168 | 0.85 | AKT1 (0.40) | NPC1RAB9AIDH2MAPTAKT1 | |
| SCHEMBL3268108 | 0.85 | MAPT (0.43) | ABCG2IDH2MAPTAKT1ADORA1 | |
| SCHEMBL3419572 | 0.83 | MEN1 (0.42) | MEN1NPC1GBA1KMT2AABCG2 | |
| SCHEMBL3238429 | 0.83 | MAPT (0.47) | MEN1NPC1GBA1KMT2AABCG2 | |
| SCHEMBL3229585 | 0.83 | SYK (0.40) | IDH2MAPTAKT1ADORA1 | |
| SCHEMBL3232908 | 0.83 | MAPT (0.48) | MEN1NPC1GBA1KMT2AABCG2 | |
| SCHEMBL3420044 | 0.81 | MEN1 (0.42) | MEN1NPC1KMT2ARAB9A | |
| SCHEMBL3264141 | 0.81 | ABCG2 (0.41) | MEN1NPC1GBA1KMT2AABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | GATAD2B, GATAD2A, RUNX1 | MEN1 1320/4885NPC1 3887/4885GBA1 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.